. 2020 Aug 3;11:3872. doi: 10.1038/s41467-020-17672-w

Table 2.

Baseline cost-effectiveness analysis in Markov models.

	Cost ($)	Incremental cost ($)	Effectiveness(QALYs)	Incremental effectiveness	ICER ($/QALY)
Patients in group I^a
The least intensive NCCN strategy	9187	0	36.049	0	0
The moderately intensive NCCN strategy	11,138	1951	36.734	0.685	2848
The most intensive NCCN strategy	15,699	6512	37.333	1.284	5072
The RTOG strategy	11,273	2050	36.780	0.732	2800
The risk-based strategy^b	9372	185	36.142	0.093	1957
Patients in group II^a
The least intensive NCCN strategy	12,479	0	26.627	0	0
The moderately intensive NCCN strategy	15,298	2819	27.596	0.969	2909
The most intensive NCCN strategy	19,911	7432	28.288	1.661	4474
The RTOG strategy	15,732	3253	27.734	1.107	2939
The risk-based strategy^b	14,869	2390	27.620	0.993	2407
Patients in group III^a
The least intensive NCCN strategy	14,815	0	21.626	0	0
The moderately intensive NCCN strategy	17,821	3006	22.514	0.888	3385
The most intensive NCCN strategy	22,135	7320	23.040	1.414	5177
The RTOG strategy	18,333	3518	22.690	1.064	3306
The risk-based strategy^b	17,864	3049	22.619	0.993	3070
Patients in group IV^a
The least intensive NCCN strategy	15,970	0	20.264	0	0
The moderately intensive NCCN strategy	19,111	3141	21.146	0.882	3561
The most intensive NCCN strategy	23,367	7397	21.645	1.381	5356
The RTOG strategy	19,546	3576	21.317	1.053	3396
The risk-based strategy^b	19,564	3594	21.377	1.113	3229

QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; NCCN, National Comprehensive Cancer Network; RTOG, Radiation Therapy Oncology Group.

^aPatients were grouped according to TNM stages and EBV DNA.

^bThe dominant strategy.